Clearbridge BioMedics

8 articles about Clearbridge BioMedics

• Clearbridge BioMedics' ClearCell FX1 System Achieves U.S. FDA listing

  1/8/2018

  Clearbridge BioMedics today announced that it has successfully registered its target cell enrichment device, the ClearCell FX1 system, with the FDA as a Class I Medical Device, for in vitro diagnostic use.

• Clearbridge BioMedics and Leica Biosystems to Co-Market Automated Solutions for Circulating Tumor Cell Analysis

  11/16/2017

  This new partnership provides an integrated and automated workflow for CTC enrichment and immunostaining, improving on major challenges in CTC liquid biopsy testing, such as handling and standardization.

• John Wayne Cancer Institute, And Clearbridge BioMedics Announce Partnership To Develop Circulating Tumor Cell Centre Of Research Excellence In The U.S.

  11/10/2016

• BGI And Clearbridge BioMedics Partner To Develop China CTC Liquid Biopsy Market Towards Precision Medicine

  5/16/2016

• National Cancer Centre Singapore, Singapore General Hospital And Clearbridge BioMedics Examine The Heterogeneity Of CTCs in Breast Cancer Patients

  4/15/2016

• Clearbridge BioMedics Partners With The The Institute of Cancer Research (ICR) And The Royal Marsden To Demonstrate Label-Free Approach In Isolating Heterogeneous Circulating Tumour Cells And PD-L1 Positive CTCs

  4/15/2016

• Sysmex Corporation And Clearbridge BioMedics To Jointly Develop New Liquid Biopsy System

  3/28/2016

• Clearbridge BioMedics Launches The ClearCell7#0174; FX System At American Society of Clinical Oncology 2014

  5/27/2014